Anthropic wants to develop its own drugs
At the event “The Briefing: AI for Science” earlier this week, Anthropic announced Claude Science, a new “AI workbench for scientists” that pulls fragmented tools and datasets into one environment, and generates figures and visuals. Anthropic, already dominating the industry with its popular coding tools and powerful AI models, framed the launch around what it says is AI’s potential to “dramatically accelerate the pace of scientific discovery and the development of healthcare interventions,” and touted a long list of biotech and pharma customers already using Claude.
Anthropic also went a step further, saying it would develop drugs of its own. Head of life sciences Eric Kauderer-Abrams said the company will focus on discovering treatments for “neglected” diseases.
AI companies have been eager to court science and pharma customers — OpenAI, Amazon, Google, and others have their own life sciences tools and platforms. But Anthropic’s...
Copyright of this story solely belongs to theverge.com. To see the full text click HERE
